Stayble Therapeutics AB has conducted a feasibility study within the project StayAble.
Main results achieved and potential impact
- The patient population was analyzed based on the extensive patient recruitment funnel to phase IB and the careful pre-screening work. This gave Stayble a precise understanding of who the patients are and how to find them for the next clinical study and commercialization. Social media proved most effective in reaching and recruiting patients and the use of social media will be critical for the recruitment to the coming trial.
- Potential co-development and commercialization partners were identified and mapped during the project. A partnering plan including target partner companies, conference and communication plan was developed. The plan has been set in action with the aim to investigate the potential to partner already before entering phase IIB.
- The financial viability of STA-363 was assessed in an rNPV model (risk-adjusted Net Present Value). Critical assumptions on market penetration, price of product, cost of clinical development and time to market were defined. The model was then qualified with industry expertise. The model has given Stayble the confidence and the tool to discuss the projections with investors and potential partners. In addition, Stayble has been able to develop rather accurate budgets for conducting clinical phase IIB and the phase III program.
Ultimately the business plan has been updated with project results and finalized, preparing Stayble for partnering, series A financing and applying to SME phase II.
